

Freedom of Information Act 2000

The Royal Cornwall Hospitals NHS Trust Response to Information request

Date Request Received: 25 10 2024

FOI Ref No: 26740

Requested Information

1. The number of patients with generalised Myasthenia Gravis (gMG) treated in each month for July, August, and September 2024
2. The volume of medication dispensed and/or consumed in each month for July, August, and September 2024 for each of the products below for gMG patients. If it is more convenient to specify the number of vials, pre-filled syringes, or tablets, that would also be very helpful.
 1. Steroids
 2. Acetylcholinesterase Inhibitors (ACHEis)
 3. Immunosuppressants
 4. Anti-CD20 - Rituximab
 5. Immunoglobulins
 6. Anti-FcRn
 7. Complement Inhibitors

Response

1. 7 separate patients are recorded as having one or more inpatient spells with ICD diagnosis codes of G70.0 or P94.0 on discharge in July 2024.
8 in August 2024
7 in September 2024

No patients are recorded as having been treated via homecare prescriptions for generalised Myasthenia Gravis (gMG) and outpatient spells are not coded in such a way as to record the diagnosis.

2. For any patient who was discharged during 2024 with a diagnosis code of G70.0 or P94.0, the following quantities of drugs were during the period of July to September 2024:
 1. Steroids (not including topical corticosteroids):
1568 mg Prednisolone
30 micrograms UMECLIDINIUM WITH VILANTEROL (ANORO)
 2. Acetylcholinesterase Inhibitors(ACHEis) :
6000 mg (PYRIDOSTIGMINE BROMIDE)

3. Immunosuppressants 0
4. Anti-CD20 – Rituximab 0
5. Immunoglobulins:
480000 mg (Gammalex, Gamunex, Octagam, Intratect)
6. Anti-FcRn 0
7. Complement Inhibitors 0

Attachment(s)

Date Response sent: